Our current study was built on the existing studies that report the value of GDF-15 quantification in predicting cardiotoxicity risk in breast cancer patients receiving trastuzumab-based treatment (Ky et al., 2014; Putt et al., 2015; Yu et al., 2018; Kirkham et al., 2022). The gene discussed is GDF15; the disease is breast carcinoma.